Pure Global: Brazil's SaMD Cyber Wall - Hacking ANVISA's Hidden MedTech Rule

In this episode, we dissect a sudden, unannounced regulatory shift from Brazil's ANVISA that is impacting the global Software as a Medical Device (SaMD) industry. Last week, the agency mandated a new, complex cybersecurity audit for all SaMD products, to be conducted exclusively by a short list of local Brazilian firms. This surprise move creates a significant new hurdle for market access. We explore the immediate consequences of this decision, discussing the operational and financial strains it places on international MedTech companies aiming to enter or expand within Latin America's largest market. Imagine your product launch, years in the making, being halted indefinitely by a bureaucratic requirement you had no way to anticipate. This is the critical pain point for SaMD manufacturers today, forcing them to scramble for local expertise and navigate a vague, complex, and costly new compliance layer. What you'll learn in this episode: - What are the specific, technical demands of ANVISA's new cybersecurity audit? - Why was this critical requirement left off the official public regulatory agenda? - How can you vet and manage the newly-approved local audit firms from abroad? - What does this move signal about Brazil's strategy for digital health sovereignty? - Are other LATAM countries like Mexico or Colombia likely to follow Brazil's lead? - How can you update your regulatory strategy to protect against these types of surprise hurdles? - What are the immediate steps to take if your SaMD submission is currently in progress? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our local experts and advanced AI-driven data tools, we provide end-to-end regulatory consulting to streamline your market access. For help navigating the complexities of the Brazilian market, contact us at [e-mail] or visit https://pureglobal.com/.